New cancer drug XB371 enters human testing for advanced tumors

NCT ID NCT07123103

Recruiting now Disease control Sponsor: Exelixis Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug, XB371, in about 150 people with advanced solid tumors that have come back or spread. The main goal is to check the drug's safety and find the best dose. Participants must be in fairly good health and have a life expectancy of at least 12 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Exelixis Clinical Site #1
RECRUITING

San Antonio, Texas, 78229, United States
Exelixis Clinical Site #2
RECRUITING

Huntersville, North Carolina, 28078, United States
Exelixis Clinical Site #3
RECRUITING

Grand Rapids, Michigan, 49546, United States
Exelixis Clinical Site #4
RECRUITING

Orlando, Florida, 32827, United States
Exelixis Clinical Site #5
RECRUITING

Rogers, Arkansas, 72758, United States
Exelixis Clinical Site #6
RECRUITING

Washington D.C., District of Columbia, 20057, United States
Exelixis Clinical Site #7
RECRUITING

New Brunswick, New Jersey, 08901, United States
Exelixis Clinical Site #8
RECRUITING

Houston, Texas, 77030, United States
Exelixis Clinical Site #9
RECRUITING

Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.